Apellis Pharmaceuticals Inc (APLS) Stock Price, Quote & News

Latest News on APLS

Apr 1, 2025, 2:11 PM EDT - 1 day ago

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals

Apr 1, 2025, 7:00 AM EDT - 1 day ago

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Mar 5, 2025, 2:06 PM EST - 4 weeks ago

Apellis Pharmaceuticals: A Mixed Bag

Mar 5, 2025, 2:04 PM EST - 4 weeks ago

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Mar 2, 2025, 2:08 AM EST - 4 weeks ago

Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 7:05 AM EST - 4 weeks ago

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 7:00 AM EST - 5 weeks ago

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 2:00 AM EST - 5 weeks ago

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

Feb 14, 2025, 7:00 AM EST - 6 weeks ago

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Feb 4, 2025, 4:05 PM EST - 2 months ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 27, 2025, 4:00 PM EST - 2 months ago

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

Jan 21, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Connect

Jan 20, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Reach Out

Jan 19, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Shareholders to Learn More About the Investigation

Jan 17, 2025, 10:00 AM EST - 2 months ago

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 16, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Investors to Learn More About the Investigation

Jan 15, 2025, 10:00 AM EST - 2 months ago

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 14, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Connect

Jan 13, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Stockholders to Inquire about Securities Investigation

Jan 13, 2025, 9:00 AM EST - 2 months ago

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

Jan 10, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Stockholders to Connect

Jan 9, 2025, 10:00 AM EST - 2 months ago

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 8, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Stockholders to Learn More About the Investigation

Jan 7, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Investors to Inquire about Securities Investigation

Jan 6, 2025, 12:30 PM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Reach Out

Jan 6, 2025, 7:00 AM EST - 3 months ago

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 27, 2024, 7:00 AM EST - 4 months ago

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Nov 5, 2024, 3:14 PM EST - 5 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 7:05 AM EST - 5 months ago

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

Oct 26, 2024, 2:00 PM EDT - 5 months ago

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

Oct 16, 2024, 2:56 PM EDT - 6 months ago

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch

Oct 4, 2024, 5:31 AM EDT - 6 months ago

Apellis: Weighing Syfovre's Rapid Expansion Against Risks In The GA Market (Rating Upgrade)

Oct 3, 2024, 12:16 PM EDT - 6 months ago

Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm

Oct 1, 2024, 1:15 PM EDT - 6 months ago

Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion

Sep 25, 2024, 7:00 AM EDT - 6 months ago

Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day

Sep 20, 2024, 5:00 AM EDT - 6 months ago

Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination

Aug 9, 2024, 5:51 AM EDT - 8 months ago

Apellis: Rare Kidney Disease Data Leads To Possible First To Market

Aug 8, 2024, 12:53 PM EDT - 8 months ago

Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases

Aug 8, 2024, 7:29 AM EDT - 8 months ago

Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN

Aug 1, 2024, 5:59 PM EDT - 8 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 7:05 AM EDT - 8 months ago

Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results

Jul 18, 2024, 7:00 AM EDT - 9 months ago

Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

Jul 9, 2024, 7:00 AM EDT - 9 months ago

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Jun 28, 2024, 6:57 AM EDT - 9 months ago

Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU

Jun 5, 2024, 7:00 AM EDT - 10 months ago

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

May 24, 2024, 10:00 AM EDT - 11 months ago

Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

May 7, 2024, 4:02 PM EDT - 11 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q1 2024 Earnings Call Transcript

May 7, 2024, 7:05 AM EDT - 11 months ago

Market Cap	2.75B
Revenue (ttm)	781.37M
Net Income (ttm)	-197.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-25.32%
Debt to Equity Ratio	1.57

Volume	2,997,400
Avg Vol	1,787,532
Day's Range	N/A - N/A
Shares Out	125.52M
Stochastic %K	41%
Beta	0.93
Analysts	Strong Sell
Price Target	$44.25